Vivos Therapeutics (NASDAQ: VVOS), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, has closed its initial public offering of 4,025,000 shares of its common stock, including an additional 525,000 shares per the full exercise of the over-allotment option granted to the underwriters. According to the update, Vivos Therapeutics secured approximately $24.2 million in gross proceeds, with each of the shares sold at the public offering price of $6.00. The common stock shares began trading on the Nasdaq Capital Market under the ticker symbol “VVOS” on Friday, Dec. 11, 2020. ROTH Capital Partners acted as the sole book-running manager for the offering.
To view the full press release, visit https://ibn.fm/FySER
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (“SDB”), including mild-to-moderate obstructive sleep apnea (“OSA”). The company believes that its products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (or “CPAP”). For more information, visit www.VivosLife.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.